Document is current
Any future updates will be listed below
-
Authors
Asmann, Yan W.
Parikh, Kaushal
Bergsagel, P. Leif http://orcid.org/0000-0003-1523-7388
Dong, Haidong http://orcid.org/0000-0002-5782-2983
Adjei, Alex A.
Borad, Mitesh J.
Mansfield, Aaron S. http://orcid.org/0000-0002-9483-6903
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R21CA251923)
- License Information
-
More Information
Article History
Received: 2 October 2020
Accepted: 18 February 2021
First Online: 19 March 2021
Competing interests
: Dr. Mansfield reports research support from Novartis and Verily; remuneration to his institution for participation on advisory boards for AbbVie, Astra Zeneca, BMS, and Genentech; travel support from Roche, and is a non-remunerated director of the Mesothelioma Applied Research Foundation. Dr. Parikh reports serving on advisory boards for AstraZeneca and Blueprint Medicines. Dr. Board reports grant funding to institution from Senhwa Pharmaceuticals, Adaptimmune, Agios Pharmaceuticals, Halozyme Pharmaceuticals, Celgene Pharmaceuticals, EMD Merck Serono, Toray, Dicerna, Taiho Pharmaceuticals, Sun Biopharma, Isis Pharmaceuticals, Redhill Pharmaceuticals, Boston Biomed, Basilea, Incyte Pharmaceuticals, Mirna Pharmaceuticals, Medimmune, Bioline, Sillajen, ARIAD Pharmaceuticals, PUMA Pharmaceuticals, Novartis, QED Pharmaceuticals, Pieris Pharmaceuticals; consulting fees to self from ADC Therapeutics, Exelixis Pharmaceuticals, Inspyr Therapeutics, G1 Therapeutics, Immunovative Therapies, OncBioMune Pharmaceuticals, Western Oncolytics, Lynx Group, Genentech, Merck, Huya; travel support to self from AstraZeneca. All other authors have no relevant competing interests to declare.
